Overview

The Effect of Low-dose Interleukin-2 on the Immune Landscape of Human Atherosclerotic Plaques at Single Cell Resolution.

Status:
ACTIVE_NOT_RECRUITING
Trial end date:
2025-09-01
Target enrollment:
Participant gender:
Summary
The goal of this clinical trail is to compare the differences in carotid plaque Treg cells' gene signature for activation, proliferation, and suppressive function using scRNA-seq in patients treated with IL-2 compared to control.
Phase:
NA
Details
Lead Sponsor:
Cambridge University Hospitals NHS Foundation Trust
Treatments:
Interleukin-2